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Targeted treatment is a therapy directed at a speciﬁc molecular target close to a hallmark of can-
cer. The target should be measurable with a biomarker and measurement of the target should
correlate with clinical outcome when targeted treatment is administered. Current clinical guide-
lines do not recommend targeted or biological therapy in MPM. However, since these recom-
mendations came out, new agents have been investigated in MPM. This review updates the
use of targeted and biological treatment in patients with mesothelioma.
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Introduction
Malignant pleural mesothelioma (MPM) is a rare and aggres-
sive neoplasm deriving from the pleural blades. More than
80% of cases are related to previous professional asbestos
exposure and its worldwide incidence is expected to further
increase [1]. Although the epidemic of asbestos-related disease
is plateauing in most of the industrialised world, little is known
about the epidemic in developing countries, where professional
and environmental exposure is increasing [2]. With a natural
history of 7–9 months if untreated and less than 5 per cent
5-year survivors, there is room for therapeutic improvement
[2]. Disease extent and performance status at diagnosis are
the clinical prognostic factors, besides epithelioid histological
subtype that confers a better outcome than the less common
sarcomatoid one.
The European Respiratory Society (ERS), the European
Society of Thoracic Surgery (ESTS) and the European
Society of Medical Oncology (ESMO) have issued recommen-
dations regarding the management of MPM [3,4]. The only
treatment with level one evidence of improvement in outcome
is the administration of palliative chemotherapy consisting of
4–6 cycles of a platinum doublet with an antifolate, either
pemetrexed or raltitrexed [5,6]. With this combination, good
performance patients have a median overall survival (OS) of
approximately 1 year and a median progression free survival
(PFS) of less than 6 months. There is no standard second line
treatment and targeted or biological treatment has no
indication in these guidelines. This review updates the use of
targeted and biological treatment in patients with advanced
MPM.Hallmarks of cancer and targeted treatment
Development of human cancers is a complex and multistep
process. Organising the factors involved in the arise and
growth of cancer is an important part of developing new treat-
ment modalities. Hallmarks of cancer include biological capa-
bilities and modulating factors to create an environment in
which cancer cells can thrive [7] (Table 1). Eight biological
capabilities allow cancer cells to survive, proliferate and
Table 1 Hallmarks of cancer and targeted treatment in MPM.
Hallmark of cancer Mechanism of counter action Target Drug Design of trial PFS (mo) MST
(mo)
OS
(mo)
Target
selection
References
Sustaining proliferative
signalling
EGFR inhibitors EGFR Geﬁtinib Single arm phase II ﬁrst line Y [12]
Erlotinib Single arm phase II ﬁrst line 2 10 Y [13]
MAb against EGFR EGFR Cetuximab Single arm phase II ﬁrst
line + platinum/pemetrexed
Y [16]
MAb against PDGFR PDGFR Imatinib Single arm phase I ﬁrst
line + platinum/pemetrexed
N [18]
Dasatinib Single arm phase II ﬁrst
line + gemcitabine
N [19]
Single arm phase II N [20]
MAb against IGFR IGFR Cixutumumab Single arm phase II in
pretreated patients
N [22]
RTK Multiple growth factors Sorafenib Single arm phase II in
pretreated patients
3.6 9.7 N [23]
Single arm phase II in
pretreated patients
5.1 N [24]
Sunitinib Single arm phase II in
pretreated patients
3.5 6.1 N [25]
Evading growth suppressors Cyclin-dependent kinase inhibitors RB1, TP53
Avoiding immune
destruction
Immune activating anti-CTL4 mAb CTL4 Tremelimumab Single arm phase II 6.2 10.7 N [29]
Phase II randomised N [30]
Anti-PDL1 PDL1 Pembrolizumab Y [31]
Anti-PD1 PD1 Nivolumab
Enabling replicative
immortality
Telomerase inhibitors
Tumour promoting
inﬂammation
Selective anti-inﬂammatory drugs
Activating invasion &
metastasis
TKI c-MET Mesothelin Tivantinib Phases I and II + cisplatin/
pemetrexed
N [34]
Phase II single agent in
pretreated patients
Y [35]
Inhibitors of HGF/c-MET Mesothelin Amatuximab Single arm phase II ﬁrst
line + cisplatin/pemetrexed
6.1 14.8 N [37]
SS1P Single arm phase II ﬁrst
line + cisplatin/pemetrexed
N [38]
Inducing angiogenesis Inhibitors of VEGF signalling VEGFR Cediranib Single arm phase II ﬁrst
line + cisplatin/pemetrexed
N [47]
Single arm phase II second
line
2.6 9.5 N [85]
Single arm phase II second
line
1.8 4.4 N [86]
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Table 1 (continued)
Hallmark of
cancer
Mechanism of counter action Target Drug Design of trial PFS
(mo)
MST
(mo)
OS
(mo)
Target
selection
Reference
Anti-VEGF targeting ligand VEGF ligand Thalidomide Phase III randomised
maintenance thalidomide
versus placebo
N [41]
Bevacizumab Single arm phase II ﬁrst
line + cisplatin/pemetrexed
N [42]
Single arm phase II ﬁrst
line + carboplatin/
pemetrexed
N [43]
Phase II randomised ﬁrst
line + cisplatin/gemcitabine
N [44]
Phase III randomised ﬁrst
line cisplatin/pemetrexed
N [45]
Vascular disrupting agents TNFa NRG-hTNF Single arm phase II in
pretreated patients
4.7 N [52]
Randomised phase II second
line versus placebo
N [53]
Maintenance after ﬁrst line
platinum/pemetrexed
N [54]
CD13 BNC105P Single arm phase II second
line
1.5 8.2 55
Genome
instability and
mutation
BAP1 Translational: prevalence of
somatic and germline
mutations
Y [61]
P16/CDKN2A (HSP90) Ganetespib Phase II randomised ﬁrst
line + cisplatin/pemetrexed
N [66]
NF2 Defactinib Phase II randomised
maintenance versus placebo
Y [68]
mTOR Everolimus Single arm phase II in
pretreated patients
N [62]
HDAC Vorinostat Phase III randomised second
line versus placebo
1.5 7 N [70]
Resisting cell
death
Proapoptotic BH3 mimetics NF-jB Bortezomib Phase II single arm second
line
2.1 5.8 N [73]
Phase II single arm ﬁrst
line + cisplatin
N [74]
Deregulating
cellular energetics
Aerobic glycolysis inhibitors Arginine ADI-PEG20 Phase II randomised Y [78]
Abbreviations: PFS: progression free survival; mo: months; MST: mean survival time; Y: yes; N: no; EGFR: epidermal growth factor receptor; Mab: monoclonal antibody; PDGFR: platelet derived
growth factor receptor; IGFR: insulin-like growth factor receptor.
RTK: receptor tyrosine kinase; RB1: retinoblastoma 1; CTL4: cytotoxic T-cell lymphocytes 4; PDL1: programmed death ligand 1; PD1: programmed death 1; HGF: hepatocyte growth factor; TKI:
tyrosine kinase inhibitor; VEGFR: vascular endothelial growth factor receptor.
TNFa: tumour necrosis factor a; NRG-hTNFa: asparagine-glycine-arginine-human tumour necrosis factor a; BAP1: BRCA1 associated protein 1; CDKN2A: cyclin-dependent kinase inhibitor 2A;
HSP90: heat shock protein 90; NF2: neuroﬁbromatosis 2; HDAC: histone deacetylase;
NF-jB: nuclear factor-jB; ADI-PEG20: arginine-lowering agent pegylated arginine deiminase.
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Mesothelioma treatment: Are we on target? 323disseminate. This is possible by two modulating characteris-
tics, genomic instability of cancer cells and the inﬂammatory
state of malignant lesions which is driven by the immune sys-
tem. Those ten hallmarks of cancer can be inﬂuenced and are
subject of investigation with therapeutic purpose. In those hall-
marks, pathways to modulate cancer cells can be activated or
inhibited. Targeted treatment is a treatment with a speciﬁc
molecular target close to those biologically important path-
ways [8]. New targeted drugs are currently under investigation.
Their target should be measurable with a biomarker and mea-
surement of the target should correlate with clinical outcome
when targeted treatment is administered. The aim is to obtain
an improved efﬁcacy – toxicity window with a minimum of
adverse effects.
This review describes the therapeutic advances made with
targeted and biological agents in MPM according to the
predominant hallmark which is targeted.Sustaining proliferative signalling
An important hallmark of cancer is the ability of tumour cells
to sustain proliferative signalling [7]. Cancer cells deregulate
the normal production and release of endogenous growth fac-
tors to increase their cell growth. Drugs have been developed
to inﬂuence those growth factors. One of the most studied
growth factors is the epidermal growth factor receptor
(EGFR) [9]. EGFR plays a role in cell proliferation, differen-
tiation, migration, adhesion and survival. The EGFR-protein
consists of an extracellular domain and a tyrosine kinase resi-
due which translates the signal to downstream intracellular
docking and signalling proteins. This kinase might be carrying
an activating driver somatic mutation which makes the tumour
addicted to growth. These activating EGFR-mutations are
however, rare in MPM [10], whereas EGFR is overexpressed
at protein level in more than 50–95% of the patients [11].
This overexpression has been associated with a better progno-
sis, probably because overexpression is more common in the
epithelioid histological type compared with the sarcomatoid
type. Anti-EGFR monoclonal antibodies (mAbs), target the
extracellular domain of EFGR and compete with the ligand
for binding. Drugs targeting the intracellular tyrosine kinase
residue are small molecule tyrosine kinase inhibitors (TKI)
such as geﬁtinib and erlotinib. Both TKI achieved
disappointing results when administered as single agents in
the treatment of pretreated patients [12,13]. Analysis of the
target biomarker showed no difference in overall survival or
response rate between high or low protein expressions.
The most likely explanation for the low efﬁcacy of EGFR
TKI is the low prevalence of activating mutations. Small mol-
ecules EGFR-TKIs have hence no place in the treatment of
MPM.
In ﬁrst line treatment, monoclonal antibodies are typically
given in combination with a standard chemotherapy back-
bone, typically platinum–pemetrexed. Cetuximab is a chimeric
mouse–human antibody targeting the extracellular domain of
EGFR. In patients with advanced non-small cell lung cancer
(NSCLC) addition of cetuximab to chemotherapy signiﬁcantly
improved overall survival compared to chemotherapy alone
[14]. Patients beneﬁting most from cetuximab were those with
a H-score at EGFR-immunohistochemistry (IHC) of more
than 200 [15]. The phase II Mesomab-trial evaluates theactivity of cetuximab in combination with 4–6 cycles of chemo-
therapy with maintenance thereafter until progression [16].
Patient selection is based on EGFR protein overexpression
by IHC. The results of this trial are awaited.
Platelet derived growth factor (PDGF) is a growth factor
inducing mesothelial cell proliferation through a similar trans-
membrane receptor, the platelet derived growth factor receptor
(PDGFR). A high serum PDGF in patients with MPM is an
independent factor of poor prognosis [17]. There seems to be
no association between IHC of PDGFR and histological
subtype. Imatinib is a TKI inhibiting among others, the
intracellular part of PDGFR. Neither as monotherapy nor in
combination with chemotherapy, a substantial activity was
however found [18,19].
Dasatinib, another TKI targeting PDGFR is also not active
as single agent and is associated with increased pulmonary
toxicity [20].
The ligand insulin-like growth factor (IGF) helps
tumour cells to grow and divide. Insulin-like growth factor
receptor (IGFR) is also expressed in MPM. The antitu-
moural effect of cixutumumab, a monoclonal antibody
against IGFR and including inhibition of the IGFR down-
stream signalling, is highly correlated with the number of
IGFR binding sites per cell [21]. Cixutumumab is currently
tested as single agent in a phase II trial in pretreated
patients with mesothelioma [22]. IGFR expression will be
correlated to response.
Several other growth factor receptors are involved in intra-
cellular signal transduction, among these vascular endothelial
growth factor receptor (VEGFR) and ﬁbroblast growth factor
receptor (FGFR). Serial or parallel activation of these recep-
tors at the protein or gene level may be a possible mechanism
of resistance to EGFR inhibition and a rationale for using
multireceptor tyrosine kinases (RTK) as sorafenib and suniti-
nib. Clinical trials with these agents in pretreated but further
target-unselected patients showed however a limited activity
[23–25].
Evading growth suppressors
Inactivation of the tumour suppressor genes the retinoblas-
toma-associated (RB1) and TP53 proteins which have an effect
on cell growth and proliferation, has not yet been described in
MPM [26]. The cyclin-dependent kinase inhibitors that typi-
cally act on both tumour suppressor genes have not yet been
tested in MPM.
Avoiding immune destruction
Tumours have evolved multiple mechanisms to evade immune
destruction [7]. Both the innate and the adaptive immune sys-
tems are able to eradicate tumour. Deﬁciencies in cytotoxic T
lymphocytes (CTLs) and natural killer (NK) cells lead to an
increased tumour incidence. With a high inﬁltration of tumour
inﬁltrating lymphocytes and macrophages and a T-cell inﬂam-
matory expression pattern, MPM can be considered as an
‘inﬂammatory’ tumour. One of the escape mechanisms to
evade immune destruction is expression of T cell inhibitory
ligands such as cytotoxic T-lymphocyte antigen 4 (CTLA4),
the programmed death 1 ligand (PD-L1) and the programmed
death 1 receptor (PD-1) [27]. PD-L1 expression in
324 B.I. Hiddinga et al.mesothelioma was correlated with a greater extent of disease at
presentation and with the sarcomatoid histological type. This
possibly explains the observed associated poor survival [28].
Immune checkpoint inhibitors block these T cell inhibitory
mechanisms and allow T cells to resume their cytotoxic activity
on cancer cells. Examples are the monoclonal antibodies
against the CTLA4 receptor, ipilimumab and tremelimumab,
against the PD-L1 and PD-1 receptor pembrolizumab and
nivolumab, respectively.
Tremelimumab was investigated in pretreated patients in a
phase II single-arm study whereby the primary endpoint of
objective response rate was not met [29]. Disease control was
noted in 31% of the patients. The median progression free sur-
vival (PFS) was 6.2 months (95% CI 1.3–11.1) and the mean
survival time (MST) was 10.7 months (0.0–21.9). In an ongo-
ing randomised phase II trial pretreated patients are allocated
to either single agent tremelimumab or placebo [30].
Monoclonal antibodies directed at the PD-L1 or PD1
receptors are currently being considered for phase 2 evaluation
in MPM [31]. More speciﬁcally, an active treatment for the sar-
comatoid subtype is unmet. This would best be studied in a
randomised ﬁrst line setting, with or versus a platinum pemetr-
exed backbone.
Enabling replicative immortality
Cancer cells require replicative potential to grow into tumours.
Telomeres are protecting the end of the chromosomes to limit
proliferation. Expression of telomeres is high in cancer cells.
Suppression of telomerase activity leads to telomere shortening
and to a proliferative barrier. Development of telomerase
inhibitors is ongoing, but presently not in MPM.Tumour promoting inﬂammation
Inﬂammation is capable of enhancing tumourigenesis by
supplying growth and survival factors that lead to activation
of hallmarks of cancer. Drugs with selectively anti-inﬂamma-
tory capabilities might have an effect in cancer treatment.
There are currently no ongoing trials in MPM targeting this
hallmark.Activating invasion and metastasis
Activating invasion and metastasis is a mechanism that was
researched for over decades and is evolving very quickly. It
is a process of local invasion, followed by intravasation by
cancer cells to nearby blood and lymphatic vessels. Finally,
extravasation leads to dissemination with growth of macro-
scopic tumours and metastases. Each of those steps can be
inﬂuenced and act as a target for novel therapies.
MET is a receptor tyrosine kinase which is activated by
binding its ligand hepatocyte growth factor (HGF) [32]. The
c-MET gene is located on chromosome 7q31 but mutations
in MET are rare in MPM [33]. The c-Met/HGF axis is
involved in cell growth, cell survival, angiogenesis, cell motil-
ity, migration and invasion and metastasis. Expression of
MET in tumour samples of MPM was increased (82%) com-
pared to normal tissue and is associated with a poor survival[33]. Serum circulating HGF was twice as high in mesotheli-
oma patients compared to healthy controls. HGF expression
seems correlated with the epithelial histological type.
Tivantinib is a small molecule TKI that selectively blocks the
MET kinase activity. In a phase I-Ib trial, tivantinib is cur-
rently evaluated in ﬁrst line with carboplatin/pemetrexed che-
motherapy [34]. In the phase II part, dynamic changes in blood
levels of HGF, vascular endothelial growth factor (VEGF),
and soluble c-Met will be evaluated.
Another phase II trial of single agent tivantinib in pre-
treated patients is conducted [35]. The translational part of
the study includes changes in baseline levels of serum HGF
and expression of MET between responders and non-respond-
ers. Also the presence of the MET gene ampliﬁcation is tested,
but is not a selection criterium for inclusion. Those biomarkers
will be correlated to change in tumour size and PFS.
Mesothelin is a differentiation and cell adhesion antigen,
whose expression is limited to the mesothelial cells lining the
pleura, pericardium and peritoneum. Its biomarker correlate
is serum mesothelin, a Food and Drug Administration
(FDA) approved biomarker of response in MPM treatment
[36].
Amatuximab is a chimeric monoclonal antibody against
mesothelin. A single arm phase II study of amatuximab plus
cisplatin and pemetrexed was initiated in ﬁrst line setting in
patients with unresectable MPM [37]. The median number of
cycles was 5 (range 1–6) and 56 patients received single agent
amatuximab. PFS at 6 months was 52% (95 CI: 39.5–63.5)
with median of 6.1 months (5.4–6.5). OS was 14.8 months.
A partial response was seen in 39% and a stable disease 51%.
SS1P is a recombinant anti-mesothelin immunotoxin con-
sisting of a murine antimesothelin variable antibody fragment.
Preclinical studies showed marked synergy between SS1P and
chemotherapy, thus initiating the phase II trial adding SS1P to
ﬁrst line cisplatin/pemetrexed [38]. In this phase II study, after
the ﬁrst cycle, all but 2 of the 21 patients (90%) developed
SS1P-neutralising antibodies. SS1P Cmax values of >150 ng/
mL were achieved during cycle 2 only by the 2 patients who
did not develop SS1P-neutralising antibodies. To overcome
this problem of neutralising antibodies, patients were pre-trea-
ted with pentostatin and cyclophosphamide that can speciﬁ-
cally deplete T and B cells and can delay antibody
formation. This treatment combination is allowing patients
to receive more cycles of SS1P [39]. Of 20 evaluable patients,
12 (60%) had a partial response (PR), 3 had stable disease
(SD), and 5 had progressive disease (PD). Of 13 patients
who received the median toxic dose (MTD), 10 (77%) had a
PR, 1 had SD, and 2 had PD. Objective radiologic responses
were associated with signiﬁcant decreases in serum mesothelin
(P= .0030), megakaryocyte potentiating factor (P= .0005),
and cancer antigen 125 (P< 0.0001). Grade 3 fatigue was
dose-limiting in 1 patient at 55 mcg/kg. The MTD of SS1P
was established as 45 mcg/kg. Other grade 3 toxicities associ-
ated with SS1P included hypoalbuminemia (21%), back pain
(13%), and hypotension (8%). The authors conclude that
SS1P given with pemetrexed and cisplatin is safe and well tol-
erated and exhibits signiﬁcant antitumour activity in patients
with unresectable, advanced pleural mesothelioma. The targets
serum mesothelin, megakaryocyte potentiating factor, and
cancer antigen 125 levels correlated with objective tumour
responses.
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An important hallmark of cancer is induction of (neo-)angio-
genesis [7]. To survive, the tumour needs a continuous supply
of nutrition and oxygen. Cancer cells do so by stimulating the
vascular endothelial growth factor receptor (VEGFR) on the
cell surface with the ligand VEGF. A high level of VEGF is
positively correlated with the microvascular density (MVD)
and associated with a poor prognosis in MPM patients [40].
Both VEGF and VEGFR are highly expressed in patients with
MPM and are used as target to block angiogenesis in tumours.
The following classes of anti-angiogenic agents have been eval-
uated in MPM:
Monoclonal antibodies
Drugs targeting the ligand VEGF are thalidomide and bev-
acizumab. Thalidomide is an old drug with presumed anti-
angiogenic properties, besides several other mechanisms of
antitumoural action. The phase III randomised NVALT5/
MATES (Maintenance Thalidomide in Mesothelioma
Patients) study, investigated the role of maintenance thalido-
mide [41]. Two-hundred-and-twenty-two patients showing dis-
ease stabilisation or response after ﬁrst line pemetrexed
chemotherapy with or without platinum were randomised
between oral thalidomide and observation. Primary endpoint
was a 50% increase in time to progression, but the hazard ratio
observed was 1.0 (p= 0.71) for time to progression and 1.2
(p= 0.30) for OS. The authors conclude that thalidomide
for switch maintenance treatment is not effective.
The administration of bevacizumab – a monoclonal anti-
body against VEGF – has been evaluated in 2 phase II studies
with either cisplatin or carboplatin in combination with
pemetrexed and was found feasible with acceptable toxicity
[42,43]. A randomised phase II trial in which bevacizumab
was added to a doublet of cisplatin/gemcitabine failed to
demonstrate a survival beneﬁt [44]. In a subgroup analysis,
patients with low baseline VEGF levels showed a beneﬁt with
bevacizumab. In the ongoing phase III Mesothelioma Avastin
Plus Pemetrexed–cisplatin (MAPS) Study, chemotherapy-
naı¨ve patients with unresectable MPM are being treated with
cisplatin/pemetrexed with or without bevacizumab [45].
Non-progressive patients in the bevacizumab arm receive bev-
acizumab till progression. The primary endpoint is overall sur-
vival (OS) and the secondary endpoint is progression-free
survival (PFS). Patients’ selection is however, not done on
baseline levels of circulating VEGF or other biomarker of
angiogenesis. Whilst accrual has been closed, the results are
currently awaited.
Small molecules
Small molecules that inhibit the VEGF tyrosine kinase recep-
tor more or less speciﬁcally are, vatalanib, cediranib, dovitinib,
pazopanib, nintedanib and axitinib. Single agent vatalanib did
not show a substantial activity in a phase II study in 47
untreated patients [46]. There was no correlation between
serum levels of VEGF, PDGF, TSP-1, or mesothelin and treat-
ment response, PFS, or survival.
Cediranib, an oral pan-inhibitor of VEGFR, c-kit and
PDGFR in combination with cisplatin/pemetrexed in ﬁrstline is currently being evaluated in phase I and PFS in
phase II [47].
Pazopanib was tested in a phase II study as single agent in
chemo-naı¨f and pretreated patients. The most frequent drug-
related toxicities were hypertension, proteinuria, liver enzyme
elevations, myelosuppression, and fatigue, all of which were
mostly grades 1–2 [48]. The primary endpoint PFS rate at six
months was 47%.
Nintedanib is a small molecule inhibiting VEGFRs 1 and 2,
FGFR and PDGFR. The safety and efﬁcacy of nintedanib is
currently evaluated in an exploratory randomised placebo con-
trolled phase II study in combination with cisplatin/pemetr-
exed in patients with unpretreated MPM. Primary endpoint
is PFS [49].
Axitinib is a small molecule inhibiting VEGFR, c-kit and
PDGFR. A randomised phase II study of axitinib in combina-
tion with cisplatin/pemetrexed showed more grade 3/4 toxicity
(neutropenia) in the axitinib group versus the chemotherapy
only group [50]. The partial response was 35% in the experi-
mental arm versus 27% in the control arm. The median PFS
was 8 versus 8.3 months. Although axitinib was well tolerated
in combination with cisplatin and pemetrexed, there was a lack
of beneﬁt in response rate, progression free or overall survival.
Dovitinib is a dual inhibitor of VEGF and FGF receptors
and is currently tested as single agent in a phase II trial in pre-
treated patients [51].Vascular disrupting agents
The primary role of tumour necrosis factor (TNF) is in the reg-
ulation of immune cells. TNF is able to induce fever, apoptotic
cell death, cachexia, inﬂammation and to inhibit tumourigene-
sis. Dysregulation of TNF production has been implicated in
cancer.
Asparagine–glycine–arginine–human tumour necrosis fac-
tor a (NGR-hTNF) exploits the tumour-homing peptide
asparagine–glycine–arginine (NGR) for selectively targeting
TNF to an aminopeptidase N/CD13 isoform overexpressed
by endothelial cells in solid tumours. NGR-hTNF has been
tested as second line treatment. A single agent phase II trial
in 57 pemetrexed-pretreated MPM patients showed a disease
control rate of 46% (95% CI: 32–59), 1 partial response, 25
stable diseases [52]. This was maintained for a median time
of 4.7 months with overall survival rates at 1, 2 and 3 years
of 47%, 16% and 8%, respectively. Based on these promising
results, a phase III NRG-015 study was initiated randomly
allocating pemetrexed-pretreated patients to investigators’
choice second line chemotherapy – vinorelbine or
doxorubicin associated with either weekly NGR-hTNF or pla-
cebo [53]. The trial has recently completed its accrual and
results are awaited.
NGR-hTNF is presently also studied in a multicentre, dou-
ble-blind, 2-arm, randomised phase 2 trial with either mainte-
nance NGR-hTNF or placebo in patients not progressing after
6 cycles of a front-line, pemetrexed based regimen [54]. The
study drug is given intravenously as 1 h infusion at 0.8 lg/m2
weekly, is started within 3–7 weeks from the last chemotherapy
cycle, until PD. Primary endpoint is PFS.
BNC105P is a tubulin polymerisation inhibitor that selec-
tively disrupts tumour vasculature and suppresses cancer cell
proliferation. In a phase II study in patients with progressive
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venously until progression or toxicity [55]. The primary end-
point was objective response rate. Although the drug was
safe and tolerable, the median PFS and OS were only
1.5 months (95% CI: 1.4–2.4) and 8.2 months (95% CI: 3.8–
11.9) respectively. These results did not warrant further
research as a single agent.
Genome instability, mutations and epigenetic dysregulation
The recent discovery of activating driver genomic alterations
has resulted in a signiﬁcant breakthrough in solid cancer ther-
apy and has changed the treatment paradigm in subsets of
patients with advanced cancers, among them, gastrointestinal
stromal tumour (GIST), melanoma, and non-small cell lung
cancer. Recent advances in massively parallel sequencing
(MPS) of tumour samples have been used to understand the
genomic proﬁle of mesothelioma. Molecular genetic analysis
has revealed genetic alterations, which are considered to be
associated and possibly driving the development and progres-
sion of MPM [56]. The most frequently mutated genes are the
cyclin-dependent kinase inhibitor 2A/alternative reading frame
(CDKN2A/ARF) on 9p21, neuroﬁbromatosis type 2 (NF2) on
22q12 and BRCA1-associated protein 1 (BAP1) on 3p21 [57].
A retrospective next-generation sequencing (NGS)-analysis of
MPM tissue samples showed that the most frequent altered
genes are adenomatous polyposis coli (APC), BAP1, colony
stimulating factor 1 receptor (CSF1R), fms-related tyrosine
kinase 3 (FLT3), NF2, kinase insert domain receptor (KDR),
phosphatidylinositol-4,5-biphosphate 3-kinase catalytic sub-
unit alpha (PIK3CA) and p53. These genomic data provide a
challenge to develop novel therapeutic targets in MPM [58].
BAP1-expression is required for vinorelbine activity and its
expression is lost in approximately 20% in patients with MPM
[59]. This hypothesis led to a study to evaluate the efﬁcacy of
second-line vinorelbine plus active symptom control (ASC),
versus ASC [60]. A study to determine the prevalence of
somatic and germline mutations in the BAP1 opened recently
and is recruiting patients [61].
Loss of function of phosphatase and tensin homologue
(PTEN), a putative protein tyrosine phosphatase gene, ampli-
ﬁes PI3K signalling and thus promotes tumourigenesis.
Activation of mTOR kinase inhibits the PI3K pathway via
negative feedback. Everolimus and sirolimus are PI3K/AKT/
mTOR pathway inhibitors. Phase II trials with everolimus
and sirolimus have given disappointing results in the treatment
of MPM [62].
Combining PI3K/AKT/mTOR pathway inhibitors with
other inhibitors might improve efﬁcacy, e.g. by the simulta-
neous inhibition of both mTOR and MEK with everolimus
and selumetinib, currently in evaluation [63,64].
Heat shock protein 90 (HSP90) is a chaperone protein that
assists other proteins to fold properly, it stabilises proteins
against heat stress, and it aids in protein degradation. It also
stabilises a number of proteins required for tumour growth
[65]. In the ongoing MESO 2 phase II study, unpretreated
patients are randomised between cisplatin/pemetrexed with
or without the oral HSP90 inhibitor, ganetespib [66].
Patients in the ganetespib group will receive this drug in main-
tenance until progression.
The NF2 tumour suppression gene encodes the protein mer-
lin. Inactivation of somatic NF2 occurs in around 40 per centof the patients with mesothelioma, leading to inactive merlin
[67]. Merlin has demonstrated a role in cell adhesion, invasion
and cell motility in tumour cell lines. Cells lacking expression
of NF2 (merlin) tumour suppression gene products are espe-
cially susceptible to focal adhesion kinase (FAK)-inhibition.
FAK may represent an important therapeutic target for
MPM, mostly in its stem cells. A new class of promising drugs
are the oral FAK – inhibitors, such as defactinib. In the ongo-
ing randomised phase II COMMAND study, patients with a
partial response or stable disease after four to six cycles of ﬁrst
line platinum–pemetrexed chemotherapy are randomly allo-
cated to a maintenance treatment with either defactinib or pla-
cebo and this until disease progression [68].
Epigenetic regulation of tumour suppressor genes through
chromatin condensation and decondensation has emerged as
an important mechanism that leads to tumourigenesis [56].
Histone deacetylase (HDAC) inhibitors target epigenetic
changes, among other mechanisms of action [69].
Vorinostat is an oral inhibitor of HDAC approved for the
treatment of cutaneous T-cell lymphoma. Initial studies of
vorinostat demonstrated objective responses in patients with
MPM. However, a recently reported phase III, randomised,
double-blind, placebo-controlled VANTAGE 014 trial was neg-
ative [70]. Patients with advanced MPM who failed prior
pemetrexed and either cisplatin or carboplatin therapy were ran-
domly allocated to receive vorinostat or placebo twice per day
for 3 of 7 days in a 3-week cycle. The MST in the intention-
to-treat population was 31 weeks in the vorinostat arm com-
pared to 27 weeks in the placebo arm, hazard ratio of 0.98
(95% CI 0.83–1.17). The median PFS time was disappointingly
not different with 6.3 weeks in the vorinostat arm and 6.1 weeks
in the placebo arm (HR= 0.75, 95% CI: 0.63–0.88). The devel-
opment of vorinostat in MPM has been halted.Resisting cell death
Programmed cell death by apoptosis is a natural mechanism in
cancer [7]. The trigger to apoptosis is DNA-damage. Necrosis
releases pro-inﬂammatory signals that recruit inﬂammatory
cells of the immune system to remove necrotic debris.
However, this inﬂammation can promote tumour by inducing
angiogenesis and cancer cell proliferation. Nuclear Factor-jB
(NF-jB) is activated by asbestos ﬁbres; this causes activation
of numerous NF-jB dependent genes, including c-myc [71].
NF-jB is upregulated in mesothelioma cells and plays an
important role in survival of these cells. Downregulation of
NF-jB and thus increasing apoptosis is a target for drugs.
Bortezomib is a small molecule proteasome inhibitor that is
blocking NF-jB and up-regulates pro-apoptotic BH3 proteins
[72]. Pre-treatment of mesothelioma cells with bortezomib
shows synergistic effect in combination with cisplatin.
Bortezomib was evaluated as a single agent in 23 pre-treated
patients but showed limited activity in this setting [73].
Partial response was conﬁrmed in one patient who received
four cycles of bortezomib and one patient had stable disease.
However, progression occurred in the majority of patients
within the ﬁrst two cycles with a median PFS and OS of 2.1
and 5.8 months, respectively. The EORTC Lung Cancer
Group (LCG) conducted a single-arm phase II study with
bortezomib and cisplatin in chemotherapy-naı¨ve patients
[74]. Primary endpoint was PFS rate at 18 weeks. Endpoint
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18 weeks had a median OS of 16.9 months compared to
11.9 months in those who progressed by 18 weeks. Toxicity
was comparable to other regimens. Although promising, the
results of the trial did not meet the predeﬁned rate of activity
at 18 weeks which would justify a phase III trial. We can con-
clude that bortezomib exhibits insufﬁcient activity to warrant
further investigation in unselected patients with mesothelioma.
Deregulating cellular metabolism
As both antifolates raltitrexed and pemetrexed, the standard
chemotherapeutic drugs used in the ﬁrst line treatment of
mesothelioma, speciﬁcally block folate-dependent enzymes in
the purine and pyrimidine biosynthesis, these drugs can be
considered targeted agents ‘avant la lettre’ [5,6].
Measurement of the expression of thymidylate synthase has
been proposed as a predictive biomarker for their use [75].
Among the different biochemical and metabolic pathway,
which can be targeted, we highlight a recent promising target
with its biomarker.
L-arginine deprivation is a novel metabolic anticancer
strategy being tested in several cancers on the basis of L-aspar-
aginase, which is an amino acid–degrading enzyme used in the
management of acute lymphoblastic leukaemia [76]. Arginine
is a semi-essential amino acid in humans. Normal argininosuc-
cinate synthetase 1 (ASS1) expressive cells are capable of form-
ing arginine. Loss of expression of ASS1 in MPM is associated
with the loss of intrinsic arginine production. Extracellular
arginine deprivation can lead to apoptosis in MPM-cells.
The ASS1 loss is tumour-type dependent, and in mesotheli-
oma, is due to promoter methylation. The expression of
ASS1 is low in 63% of MPM [77]. The phase II Arginine
Deiminase and Mesothelioma (ADAM) randomised patients
with ASS1-deﬁcient advanced MPM between best supportive
care (BSC) with or without the arginine-lowering agent pegy-
lated arginine deiminase (ADI-PEG20) intramuscular injection
320 UI/m2/week [78]. The primary endpoint was PFS. Almost
doubling of the PFS was observed, with a median PFS of
98 days for the experimental arm and 59 days for the control
arm with a PFS HR 0.53 (95% CI 0.31–0.90), favouring
ADI-PEG20. No objective responses were recorded. The drug
was generally safe and well tolerated. However, a mechanism
of resistance to ADI-PEG20 was noticed with the development
of antidrug neutralising antibodies that peak by day 50 with a
concomitant increase in plasma L-arginine levels [79].
The phase II TRAP (tumours requiring arginine to assess
ADI-PEG20 with Pemetrexed and cisplatin) trial is combining
arginine deprivation therapy with chemotherapy. ASS1
negative patients will be randomised to cisplatin/pemetrexed
and ADI-PEG20 or cisplatin/pemetrexed alone [78].
Discussion and future directions
Many hallmarks are still to be explored, as enabling replicative
immortality and tumour promoting inﬂammation and corre-
sponding targeted new drugs to be developed. Podoplanin is
highly expressed in MPM. Podoplanin antibodies inhibiting
platelet aggregation and hematogenous metastasis might be
useful in the future [80]. Small molecule inhibitor of CARP-
1, a peri-nuclear phosphoprotein that is a regulator of cancercell growth and apoptosis signalling, might be effective in the
treatment of MPM and is in development [81]. Cilengitide, a
synthetic peptide inhibitor that induces growth inhibition is
currently tested in phase III in lung carcinoma. In MPM cell
lines it is currently tested preclinically [82].
Combination of therapies directed at different targets, as
with EGFR and MET inhibitors, has a stronger effect than
targeting either factor alone [83]. Dual targeting of pathways
can be more efﬁcacious on mesothelioma proliferation and via-
bility than inhibition of an individual pathway [84].
Conclusions
Are we on target? Not yet! We have too many targets but few
validated biomarkers. A true breakthrough has still to be
obtained, as the development of targeted agents in MPM suf-
fers from the same weaknesses as in non-small cell lung cancer:
poor target deﬁnition and inappropriate trial design. Most
studies were conducted in a biomarker unselected patient pop-
ulation, either because no valid biomarker is available – as in
angiogenesis – or an inappropriate expression technique for
the marker was used, as with immunohistochemistry for tyrosine
kinase inhibitors. The future lies in randomised phase II trials
with the targeted agent added to or compared to a standard che-
motherapy backbone in ﬁrst line and in proof of concept trials in
pretreated patients, both stratiﬁed for or restricted to patients
with a valid target expression. Referral of patients in a good
performance status into these trials is highly recommended.
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